Hrain Biotechnology Co., Ltd. is located in Shanghai Zhangjiang Hi-Tech Park. Adhering to the idea of relieving patients from diseases, focusing on R&D and application of tumor immunotherapy technologies and the transformation of the latest foreign tumor immunotherapy technologies, we have always been an active promoter for the innovative tumor immunotherapy technologies and a provider of advanced precision treatment solutions for cancer patients.
Hrain is a high-tech biotechnology company founded by a team of internationally renowned scientists.In addition, our management and research team is very competitive with the senior professionals from domestic and international universities. Among the staff, those with a doctoral degree make up 21%, those with a master’s degree 79%, those trained overseas 16% and those from the Top 20 domestic universities in China over 67%.
Hrain has a R&D pattern of one center and multiple highlights, with CAR-T technology as the center while CAR-NK, new DC vaccines, iNKT and other technologies being promoted in parallel. We have several CAR-T clinical trials registered on ClinicalTrials.gov, an authoritative platform for exchanges of clinical experience in America, and we also have multiple clinical centers located in Beijing, Chongqing, Jiangsu, Zhejiang, Henan, Jiangxi, etc. Our clinical trial now could be carried out in the United States, Europe and the Middle East and will extend its reach to more countries in this regard. Together with Elsevier, a world's leading publisher in technology and medicine, Hrain has launched the Journal of Cellular Immunotherapy, the only China’s English journal on cellular immunotherapy published worldwide.
"Supreme Good, Moral Integrity, Social Welfare and Vigorous Life” are the targets for Hrain. We will continue to be precise, realistic, innovative and pioneering and advance the medical development as we always do; finally, we will be the most powerful health guardian for Chinese people!